卡瑞利珠单抗联合安罗替尼在晚期食管鳞癌患者一线治疗中的疗效分析

Analysis of the Efficacy of Camrelizumab Combined with Anlotinib in the First-line Treatment of Patients with Advanced Esophageal Squamous Carcinoma

目的探讨卡瑞利珠单抗联合安罗替尼在晚期食管鳞癌患者一线治疗中的疗效。方法方便选取2022年5月—2023年6月于徐州医科大学附属医院诊治的113例晚期食管鳞癌患者作为研究对象,利用随机数表法分为对照组(56例)和研究组(57例)。对照组给予盐酸安罗替尼胶囊联合化疗一线治疗,研究组在对照组基础上联合卡瑞利珠单抗。比较两组患者临床疗效、治疗前后肿瘤标志物水平及不良反应发生情况。结果两组患者疾病缓解率对比,差异无统计学意义(P>0.05);研究组疾病控制率高于研究组,差异有统计学意义(P<0.05)。治疗前,两组患者肿瘤标志物水平比较,差异无统计学意义(P>0.05);治疗后,研究组肿瘤标志物水平低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率对比,差异无统计学意义(P>0.05)。结论将卡瑞利珠单抗与安罗替尼联合应用于晚期食管鳞癌患者的一线治疗中,能够有效降低肿瘤标志物的水平,有利于疾病控制,并且不会增加患者的不良反应。

Objective To explore the efficacy of camrelizumab combined with anlotinib in the first-line treatment of patients with advanced esophageal squamous carcinoma.Methods 113 patients with advanced esophageal squamous carcinoma admitted to the Affiliated Hospital of Xuzhou Medical University from May 2022 to June 2023 were conveniently selected as study subjects.They were divided into control group(56 cases)and study group(57 cases)by random number table method.The control group was given anlotinib hydrochloride capsule combined with chemotherapy for first-line treatment,and the study group was combined with carrilizumab based on the control group.The clinical efficacy,the level of tumor markers before and after treatment,and the occurrence of adverse reactions were compared between the two groups.Results There was no significant difference in disease remission rate between the two groups(P>0.05).The disease control rate of the study group was higher than that of the study group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the level of tumor markers between the two groups(P>0.05).After treatment,the level of tumor markers in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of carrellizumab and antirotinib in the first-line treatment of patients with advanced esophageal squamous cell carcinoma can effectively reduce the level of tumor markers,which is conducive to disease control,and does not increase the adverse reactions of patients.